Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: Are the reagents beneficial or harmful?

被引：30

作者：

Chen, Rui ^{[1
,2
]}

Liang, Fengxia ^{[3
,4
]}

Moriya, Junji ^{[1
]}

Yamakawa, Jun-ichi ^{[1
]}

Takahashi, Takashi ^{[3
]}

Shen, Lin ^{[2
]}

Kanda, Tsugiyasu ^{[1
]}

机构：

[1] Kanazawa Med Univ, Dept Gen Med, Uchinada, Ishikawa 9200293, Japan

[2] Huazhong Univ Sci & Technol, Union Hosp, Dept Tradit Chinese Med, Wuhan 430074, Peoples R China

[3] Hubei Coll Tradit Chinese Med, Wuhan, Peoples R China

[4] Kanazawa Med Univ, Dept Endocrinol, Uchinada, Ishikawa 9200293, Japan

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2008年 / 130卷 / 02期

关键词：

Peroxisome proliferator-activated receptors; Heart failure; Hypertension; Blood pressure; Contractile function;

D O I：

10.1016/j.ijcard.2008.03.080

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Peroxisome proliferator-activated receptors (PPARs) alpha and gamma regulate nearly every step in cellular fatty acid uptake, utilization, oxidation, and storage pathways. They also control cell growth and migration, oxidative stress, and inflammation in the cardiovascular system. Recent studies have shown that PPARs have paradoxical effects on cardiovascular diseases, especially hypertension and heart failure. It is still unclear whether the blood pressure increases or decreases after treatment with a PPAR alpha agonist; it is also uncertain whether PPAR agonists are beneficial or harmful for heart failure. In order to clarify these issues, the literature on PPAR alpha and gamma and their agonists, as well as their effect on hypertension and heart failure not only in humans but also in experimental animals, was reviewed. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：131 / 139

页数：9

共 81 条

[1]

ANVERSA P, 1989, INT J MICROCIRC, V8, P353

[2] Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice [J].

Bernal-Mizrachi, C ;

Weng, S ;

Feng, C ;

Finck, BN ;

Knutsen, RH ;

Leone, TC ;

Coleman, TY ;

Mecham, RP ;

Kelly, DP ;

Semenkovich, CF .

NATURE MEDICINE, 2003, 9 (08) :1069-1075

[3] An afferent vagal nerve pathway links hepatic PPARα activation to glucocorticoid-induced insulin resistance and hypertension [J].

Bernal-Mizrachi, Carlos ;

Liu Xiaozhong ;

Li Yin ;

Knutsen, Russell H. ;

Howard, Michael J. ;

Arends, Joop J. A. ;

DeSantis, Pascual ;

Coleman, Trey ;

Semenkovich, Clay F. .

CELL METABOLISM, 2007, 5 (02) :91-102

[4] Peroxisome proliferator-activated receptors in the cardiovascular system [J].

Bishop-Bailey, D .

BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (05) :823-833

[5] Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].

Braissant, O ;

Foufelle, F ;

Scotto, C ;

Dauca, M ;

Wahli, W .

ENDOCRINOLOGY, 1996, 137 (01) :354-366

[6] The PPARα activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy [J].

Brigadeau, Francois ;

Gele, Patrick ;

Wibaux, Maud ;

Marquie, Christelle ;

Martin-Nizard, Francoise ;

Torpier, Gerard ;

Fruchart, Jean-Charles ;

Staels, Bart ;

Duriez, Patrick ;

Lacroix, Dominique .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (06) :408-415

[7] PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse [J].

Calkin, Anna C. ;

Giunti, Sara ;

Jandeleit-Dahm, Karin A. ;

Allen, Terri J. ;

Cooper, Mark E. ;

Thomas, Merlin C. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) :2399-2405

[8] Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells [J].

Calnek, DS ;

Mazzella, L ;

Roser, S ;

Roman, J ;

Hart, CM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :52-57

[9] Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors [J].

Campia, U ;

Matuskey, LA ;

Panza, JA .

CIRCULATION, 2006, 113 (06) :867-875

[10] Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats [J].

De Ciuceis, C. ;

Amiri, F. ;

Iglarz, M. ;

Cohn, J. S. ;

Touyz, R. M. ;

Schiffrin, E. L. .

BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (01) :45-53

← 1 2 3 4 5 6 7 8 9 →